ClinicalTrials.gg
RecruitingNCT06882096Updated May 6, 2025

Tracing the Metabolic Flux of Orally Administered NAD+ Precursors

A Phase 1 interventional study of Nicotinamide Mononucleotide (NMN) and Nicotinamide (NAM) in Healthy Adults, sponsored by Metro International Biotech, LLC. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by Metro International Biotech, LLC · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+. NAD+ is a natural substance that cells need for energy and other important processes. Our goal is to find out how these NAD precursors are absorbed and metabolized and how they raise NAD+ in different tissues.

Who can join? Healthy adults men and women aged 18 to 40 (younger group) or 65 and older (older group) Participants with a body mass index ranging between 19 and 35 No major health issues like diabetes or severe kidney disease

What will happen? Participants will take labeled or unlabeled NMN or NAM by mouth every day for 14 days.

Researchers will collect blood, urine, and stool samples. Researchers also do a small muscle biopsy (under local numbing) twice to check how these NAD precursors raise NAD+ in muscle.

Why is this important? NAD+ levels may drop as people age, and this drop could affect overall health and energy in cells.

A better understanding of how NMN and NAM are metabolized in the body to raise NAD+ levels in both younger and older adults may help us optimize dosing and strategies for raising NAD in older people.

Possible benefits and risks:

Participants may not get any direct health benefit from this study; the main goal is to gather new knowledge.

NMN and NAM appear safe in the doses used. A muscle biopsy may cause soreness or bruising.

Researchers will monitor participants closely for any side effects throughout the study.

Read the detailed description

Background and Significance

1.1 Role of NAD+ in Physiology Nicotinamide adenine dinucleotide (NAD+) is a key coenzyme in all living organisms, existing in oxidized (NAD+) and reduced (NADH) forms. Beyond its vital role in redox reactions and ATP generation, NAD+ also serves as a co-substrate for several signaling enzymes such as sirtuins, PARPs, and CD38. Systemic NAD+ insufficiency can cause diseases like pellagra; reduced NAD+ availability has been implicated in aging and age-related disorders.

1.2 Oral NAD+ Precursors Administration of NAD+ precursors (e.g., NMN, NR, NAM) can boost NAD+ levels. Although human research has shown that oral NMN raises blood NAD+ concentrations, many aspects of its absorption, metabolism, and overall bioavailability are still poorly understood. Rodent studies suggest oral NMN undergoes extensive first-pass metabolism in the gut, with partial conversion to NAM prior to entering systemic circulation.

1.3 Aging and NAD+ In rodent models, NAD+ levels frequently decline as the animals get older. Some evidence indicates that NAD+ turnover may be elevated in aging rodents, suggesting a higher rate of NAD+ consumption. However, equivalent tracer studies have not yet been conducted in humans.

1.4 Need for Human Tracer Studies These compounds are being investigated for the prevention and treatment of age-related diseases. There is a need to clarify how they are absorbed and how exactly they elevate NAD+ in different tissues. Using stable isotope-labeled NMN and NAM will help map the flux from oral precursors into blood, muscle, urine, and stool, and will also reveal how aging influences NAD+ turnover.

  1. Aims and Objectives

Aim 1: Use stable isotope tracers and mass spectrometry in healthy young adults to track how orally administered NMN or NAM are metabolized, how they enter NAD+ pools, and how much is excreted or converted to other metabolites.

Aim 2: Compare these same fluxes in older adults (≥65 years). Investigators specifically want to see whether age alters the metabolic route from precursor to NAD+ and whether older adults exhibit higher consumption (turnover) of NAD+.

  1. Study Design

3.1 Overview Single-center trial at Brigham and Women's Hospital.

Groups: Two main groups of participants:

Group A (NMN group): 16 participants (8 young adults aged 18-40; 8 older adults aged ≥65).

Group B (NAM group): 16 participants (8 young; 8 older). Each participant takes either NMN or NAM orally for 14 days. The study uses stable isotopes (non-radioactive) to label NMN or NAM in order to track how these molecules appear in NAD+ and its downstream metabolites.

3.2 Treatment Duration Participants receive daily doses of their assigned treatment (NMN or NAM) for 14 days. Detailed sampling done on Days 1 and 14.

3.3 Dosage NMN: 1000 mg once daily (four 250 mg capsules). NAM: 370 mg once daily. On Days 1 and 14, the entire oral dose is fully labeled with stable isotopes; on the intermediate days (2-13), the product is unlabeled.

3.4 Key Assessments Blood draws at multiple time points (e.g., pre-dose, 30 min, 1 hr, 2 hr, 4 hr, 8 hr) on Days 1 and 14.

Muscle biopsies of the vastus lateralis (Days 1 and 14, typically \~6-8 hours after dose) to determine how much labeled precursor appears in muscle NAD+ pools.

Timed Collection of urine and stool on Days 1-2 and 14-15 to see how the precursor or NAD+ metabolites are excreted and to characterize gut microbiome (which can influence NAD+ precursor metabolism and may be affected by NMN or NAM).

  1. Endpoints

Primary Endpoints (for NMN group) Fraction of peripheral blood NAD+ containing the stable isotope labelled tracer

Primary Endpoints (for NAM group) Fraction of peripheral blood NAD+ containing the stable isotope labelled tracer

  1. Study Procedures Screening Phase (up to 4 weeks before Day 1) Medical history, demographics, laboratory tests (CBC, chemistry, A1C), physical exam, and EKG if indicated.

Confirm eligibility. Intervention Phase (Days 1-14)

Day 1:

Collect baseline blood samples and muscle biopsy. Blood draws at multiple time points (e.g., pre-dose, 30 min, 1 hr, 2 hr, 4 hr, 8 hr).

Administer stable-isotope-labeled product (NMN or NAM) at time 0. Repeat blood draws at specified intervals. Collect urine and stool.

Day 2:

Additional blood draws. Begin taking unlabeled study product daily at home.

Days 3, 5, 8:

Short visits for blood sampling, vital signs, adherence check.

Day 14:

Collect baseline blood samples and muscle biopsy. Blood draws at multiple time points (e.g., pre-dose, 30 min, 1 hr, 2 hr, 4 hr, 8 hr).

Administer stable-isotope-labeled product (NMN or NAM) at time 0. Collect urine and stool.

Day 15:

Unlabeled Treatment (NAM or NMN) administration. Follow-up blood draws.

Follow-up Phase:

Days 16, 43:

Final safety labs, check for adverse events, measure any labeled/unlabeled NAD+ or metabolites that might linger.

  1. Risks and Safety

Drug Safety:

Previous Phase 1 trials show 1000 mg NMN up to twice daily is safe and well-tolerated, with no serious drug-related adverse events.

NAM is generally recognized as safe at these doses. High-dose niacin can cause flushing, GI disturbance, or liver enzyme elevations, but those have not been seen with NMN or NAM.

Muscle Biopsy:

Potential for temporary discomfort, bruising, or rare infection at the biopsy site. The team will use local anesthetic and standard sterile technique.

Blood Draws:

Common risks include transient pain or bruising, and rarely infection.

Urine and Stool Collection:

Main risk is inconvenience and mild discomfort; no significant medical risk from the collection itself.

Adverse Events Reporting:

The protocol specifies regular monitoring and reporting. A Safety Review Committee (SRC) meets every six months.

  1. Statistical Analysis

Primary Analyses:

Quantify the fraction of labeled NAD+ vs. unlabeled in blood, PBMCs, muscle, urine, and stool.

Compare young vs. older adults to see whether aging shifts the route or magnitude of NAD+ precursor metabolism.

Models:

Mixed-model repeated measures (MMRM) or ANCOVA with factors for age, sex, and baseline values.

Sample Size:

16 subjects per arm (8 young + 8 older in NMN group; 8 young + 8 older in NAM group) is based on pilot data and the specialized nature of stable-isotope tracing.

  1. Study Conduct and Logistics

Randomization:

1:1 ratio to NMN vs. NAM, block-randomized, stratified by age group.

Blinding:

The protocol is an open-label comparison of two labeled precursors.

Data Management:

Electronic CRFs, redcap database, verification by investigators.

Monitoring:

Internal team plus sponsor oversight.

Ethical Considerations:

IRB approval, informed consent detailing objectives, procedures, and risks. Emphasis on ensuring participant safety.

  1. Importance and Potential Impact

The protocol addresses critical gaps in knowledge like how orally ingested NAD+ precursors (NMN, NAM) become NAD+ in human tissues.

Results will inform whether older adults have distinctly higher NAD+ turnover and might respond differently to NAD+ augmentation.

Findings could shape clinical dosing recommendations for NMN/NAM in therapeutic or preventive settings related to aging and metabolic health.

02

Conditions studied

  • Healthy Adults
03

In context

Lead sponsor

Metro International Biotech, LLC is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A participant may be enrolled if he/she is:

  1. A healthy, community-living, man or a woman between 18 and 40 years, inclusive or 65 years or older
  2. Has a (BMI) between 19 and 35 kg/m2, inclusive
  3. Is free from medical problems as determined by the Investigator
  4. Is capable of providing written .
  5. Is willing and able to provide authorization for the use and disclosure of personal health information in accordance with Health Insurance Portability and Accountability Act.

Exclusion criteria

EXCLUSION CRITERIA

A subject may not be enrolled if s/he:

  1. Has or ALT > 2 times the
  2. Hematocrit \< 36% or > 51% for men, or \< 35% to > 48% for women
  3. Diagnosis of diabetes, using diabetes medications or an > 6.4%
  4. Serum creatinine > 2.0 mg/dL or \<60 mL/min
  5. Prohibited medications and substances: use of anabolic steroids, rhGH, DHEA, androstenedione, or any performance enhancing drug; Current use of opiates, amphetamine, cannabinoids and cocaine
  6. Use of any dietary supplement. Subjects who are using a supplement containing NAM (or niacin or NMN or NR) may be included if they agree to stop supplement at least 2 weeks before randomization.
  7. For women only: Pregnant or planning to get pregnant over the next 6 months, or lactating
  8. Participation in an trial within the past 3 months
  9. Other medical conditions which, in the opinion of the investigator, would jeopardize safety or impact the validity of the study results

For women only:

Female of childbearing age: Use of oral is allowed provided the contraceptive regimen was initiated at least 3 months before randomization and the participant agrees not to change the regimen during the course of the study.

Excluded Medications and Treatments

  1. The ingestion of the following is prohibited during 14 days prior to Day 0 and for the duration of the intervention period:

    • Products that contain niacin, nicotinic acid, nicotinamide in any form, other than natural foods
    • Herbal supplements
  2. Treatment with another investigational drug, investigational device, or approved therapy for investigational use within 3 month is prohibited.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Active comparator
    NMN- Nicotinamide Mononucleotide

    This arm will include 16 participants (8 young and 8 older adults) who will receive NMN once daily for 14 consecutive days.

    Drug: Nicotinamide Mononucleotide (NMN)

  • Active comparator
    NAM- Nicotinamide

    This arm will include 16 participants (8 young and 8 older adults) who will receive NAM once daily for 14 consecutive days.

    Drug: Nicotinamide (NAM)

Interventions

06

What researchers measure

Primary outcomes

  1. Labelled NAD+ in Peripheral Blood

    Quantify the fraction of peripheral blood. NAD+ containing the stable isotope labelled tracer

    Time frame: During the Study Intervention Period Day 1 through Day 14

Secondary outcomes

  1. Labelled NAD+ in Muscle

    Quantify the fraction of muscle NAD+ containing the stable isotope labelled tracer

    Time frame: During the Study Intervention Period Day 1 through Day 14

  2. 1-Methyl nicotinamide (MeNAM) in Plasma

    Measure the labelled reading of Plasma NAD+ metabolite 1-Methyl nicotinamide (MeNAM)

    Time frame: During the Study Intervention Period Day 1 through Day 14

  3. 1-Methyl nicotinamide (MeNAM) in Muscle

    Measure the labeled reading of Muscle NAD+ metabolite 1-Methyl nicotinamide (MeNAM)

    Time frame: During the Study Intervention Period Day 1 through Day 14

  4. 1-Methyl nicotinamide (MeNAM) in Urine

    Measure the labeled reading of Urine NAD+ metabolite 1-Methyl nicotinamide (MeNAM)

    Time frame: During the Study Intervention Period Day 1 through Day 14

  5. 1-Methyl nicotinamide (MeNAM) in Stool

    Measure the labeled reading of Stool NAD+ metabolite 1-Methyl nicotinamide (MeNAM)

    Time frame: During the Study Intervention Period Day 1 through Day 14

  6. N-methyl-2-pyridone-5-carboxamide (2PY) in Plasma

    Measure the labeled reading of Plasma metabolite N-methyl-2-pyridone-5-carboxamide (2PY)

    Time frame: During the Study Intervention Period Day 1 through Day 14

  7. N-methyl-2-pyridone-5-carboxamide (2PY) in Muscle

    Measure the labeled reading of Muscle NAD+ metabolite N-methyl-2-pyridone-5-carboxamide (2PY)

    Time frame: During the Study Intervention Period Day 1 through Day 14

  8. N-methyl-2-pyridone-5-carboxamide (2PY) in Urine

    Measure the labeled reading of Urine NAD+ metabolite N-methyl-2-pyridone-5-carboxamide (2PY)

    Time frame: During the Study Intervention Period Day 1 through Day 14

  9. N-methyl-2-pyridone-5-carboxamide (2PY) in Stool

    Measure the labeled reading of Stool NAD+ metabolite N-methyl-2-pyridone-5-carboxamide (2PY)

    Time frame: During the Study Intervention Period Day 1 through Day 14

  10. Nicotinamide in Plasma

    Measure the labeled reading of Plasma NAD+ metabolite- Nicotinamide

    Time frame: During the Study Intervention Period Day 1 through Day 14

  11. Nicotinamide in Muscle

    Measure the labeled reading of Muscle NAD+ metabolite Nicotinamide

    Time frame: During the Study Intervention Period Day 1 through Day 14

  12. Nicotinamide in Urine

    Measure the labeled reading of Urine NAD+ metabolite Nicotinamide

    Time frame: During the Study Intervention Period Day 1 through Day 14

  13. Nicotinamide in Stool

    Measure the labeled reading of Stool NAD+ metabolite Nicotinamide

    Time frame: During the Study Intervention Period Day 1 through Day 14

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Sauve AA, Wang Q, Zhang N, Kang S, Rathmann A, Yang Y. Triple-Isotope Tracing for Pathway Discernment of NMN-Induced NAD+ Biosynthesis in Whole Mice. Int J Mol Sci. 2023 Jul 5;24(13):11114. doi: 10.3390/ijms241311114. PubMed 37446292 ↗
  • Amjad S, Nisar S, Bhat AA, Shah AR, Frenneaux MP, Fakhro K, Haris M, Reddy R, Patay Z, Baur J, Bagga P. Role of NAD+ in regulating cellular and metabolic signaling pathways. Mol Metab. 2021 Jul;49:101195. doi: 10.1016/j.molmet.2021.101195. Epub 2021 Feb 17. PubMed 33609766 ↗
  • Pencina KM, Lavu S, Dos Santos M, Beleva YM, Cheng M, Livingston D, Bhasin S. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. J Gerontol A Biol Sci Med Sci. 2023 Jan 26;78(1):90-96. doi: 10.1093/gerona/glac049. PubMed 35182418 ↗
  • Pencina KM, Valderrabano R, Wipper B, Orkaby AR, Reid KF, Storer T, Lin AP, Merugumala S, Wilson L, Latham N, Ghattas-Puylara C, Ozimek NE, Cheng M, Bhargava A, Memish-Beleva Y, Lawney B, Lavu S, Swain PM, Apte RS, Sinclair DA, Livingston D, Bhasin S. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1968-1980. doi: 10.1210/clinem/dgad027. PubMed 36740954 ↗
  • Dutta T, Kapoor N, Mathew M, Chakraborty SS, Ward NP, Prieto-Farigua N, Falzone A, DeLany JP, Smith SR, Coen PM, DeNicola GM, Gardell SJ. Source of nicotinamide governs its metabolic fate in cultured cells, mice, and humans. Cell Rep. 2023 Mar 28;42(3):112218. doi: 10.1016/j.celrep.2023.112218. Epub 2023 Mar 9. PubMed 36897780 ↗
  • Kim LJ, Chalmers TJ, Madawala R, Smith GC, Li C, Das A, Poon EWK, Wang J, Tucker SP, Sinclair DA, Quek LE, Wu LE. Host-microbiome interactions in nicotinamide mononucleotide (NMN) deamidation. FEBS Lett. 2023 Sep;597(17):2196-2220. doi: 10.1002/1873-3468.14698. Epub 2023 Aug 9. PubMed 37463842 ↗
  • Xiao W, Wang RS, Handy DE, Loscalzo J. NAD(H) and NADP(H) Redox Couples and Cellular Energy Metabolism. Antioxid Redox Signal. 2018 Jan 20;28(3):251-272. doi: 10.1089/ars.2017.7216. Epub 2017 Jul 28. PubMed 28648096 ↗
  • Chellappa K, McReynolds MR, Lu W, Zeng X, Makarov M, Hayat F, Mukherjee S, Bhat YR, Lingala SR, Shima RT, Descamps HC, Cox T, Ji L, Jankowski C, Chu Q, Davidson SM, Thaiss CA, Migaud ME, Rabinowitz JD, Baur JA. NAD precursors cycle between host tissues and the gut microbiome. Cell Metab. 2022 Dec 6;34(12):1947-1959.e5. doi: 10.1016/j.cmet.2022.11.004. PubMed 36476934 ↗
  • Bhasin S, Seals D, Migaud M, Musi N, Baur JA. Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns. Endocr Rev. 2023 Nov 9;44(6):1047-1073. doi: 10.1210/endrev/bnad019. PubMed 37364580 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 18, 2025
StartActual
Apr 28, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06882096
Lead sponsor
Metro International Biotech, LLC
Responsible party
Shalender Bhasin (Principal Investigator, Metro International Biotech, LLC) — Principal investigator
First posted
Mar 18, 2025
Start date
Apr 28, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 6, 2025

Study contacts

Mohan Sonu Chandra, MB,BS
Contact
mchandra@bwh.harvard.edu
617-525-9154
Nancy K Latham, PhD
Contact
nklatham@bwh.harvard.edu
617-999-9195
Shalender Bhasin, MB, BS
principal investigator · Brigham and Women's Hosptial

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nicotinamide Mononucleotide · Niacinamide

Start the discussion